A U.S. District Court ruling issued September 2, 2026 has invalidated two patent claims Kaneka Corporation asserted against Cocrystal Technology (Jiaxing) Co., Ltd., clearing the Chinese ingredient supplier to manufacture and sell its reduced coenzyme Q10 (ubiquinol) ingredient — now rebranded as CrysQnol™ — across the United States without restriction.
The Eastern District of New York court found, on summary judgment, that Kaneka's U.S. Patent No. 7,829,080 failed to meet the utility and enablement requirements of U.S. patent law. The judge noted that Kaneka's asserted invention rested on an untested hypothesis and that even the patent's own inventors and expert witnesses could not demonstrate or explain how coenzyme Q11 — a naturally occurring minor component in CoQ10 materials — would produce any stabilizing effect. With judgment entered in Cocrystal Tech's favor, the case is closed.
What It Means for Formulators
For nutraceutical brand owners, contract manufacturers (CMOs), and distributors, the ruling removes a meaningful sourcing risk that had shadowed the ingredient since Kaneka filed suit in October 2023. Cocrystal Tech stipulated throughout litigation that its product fell within the literal language of the asserted claims — meaning the legal cloud was real — but it consistently argued the claims themselves were invalid. With that question now settled, supply-chain decision-makers can evaluate CrysQnol™ on technical and commercial grounds: stability, bioavailability, formulation flexibility, and cost efficiency, without patent exposure. That matters especially in the active nutrition and functional food segments, where ingredient sourcing decisions carry both regulatory and commercial weight.
"Our focus has never been on following an established path, but on solving difficult scientific problems through our own research and technology," said Dr. Xuefeng Mei, Founder of Cocrystal Tech. "The ruling marks not an endpoint, but an opportunity to bring our technology to more customers and continue innovating in the U.S. market."
Rebrand and Portfolio Expansion
Cocrystal Tech is using the legal resolution as a commercial inflection point. The company — which previously marketed the same ubiquinol ingredient under the Crystal QH® trademark — has initiated a full transition to the CrysQnol™ brand across its global trademark portfolio. The company says customers can expect full formulation and specification continuity through the changeover.
CrysQnol™ sits within a broader ingredient lineup built on Cocrystal Tech's proprietary Cocrysta™ cocrystal stabilization platform, which also underpins CurCutine™ (curcumin), Precitein™, and UroRenu™. The company positions pharmaceutical-grade cocrystal technology as a differentiated tool for improving the stability and bioavailability of high-demand nutraceutical compounds — a claim that becomes more commercially credible now that U.S. legal uncertainty has been resolved.
The ruling arrives as competition in the global ubiquinol market intensifies and functional ingredient sourcing draws increasing scrutiny from operators building wellness-forward menu and product strategies. With supply now legally unencumbered, Cocrystal Tech is positioned to deepen distribution across North America, where the company says its ingredients are already trusted by leading brands in the supplement and functional food space.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
